New skin patch could speed recovery after skin cancer removal

NCT ID NCT07695389

Not yet recruiting Disease control Sponsor: BioLab Holdings Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial tests whether a new skin graft substitute (CAMP) plus standard wound care helps wounds heal faster after Mohs surgery for skin cancer compared to standard care alone. About 160 adults who have had Mohs surgery for a skin cancer will be randomly assigned to receive either the CAMP product or standard care for up to 6 weeks. The main goal is to see if the CAMP product leads to complete wound closure within 6 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: caregraFT™ (a cellular, acellular, matrix-like product)
What this could lead to: If it works, this could offer a faster, more reliable way to heal wounds after skin cancer surgery, reducing recovery time and scarring.
What could go wrong: This is a Phase 4 trial with 160 participants, so results may not apply to everyone. The product could cause infection, allergic reaction, or fail to improve healing over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma skin cancer squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS MALIGNANCY MOHS SURGICAL DEFECT UNDERGONE MOHS MICROGRAPHIC SURGERY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.